The devastating consequences of venous thromboembolism have forever provided the impetus to explore safe and effective treatment strategies. To date, the pathophysiology and mechanism of thrombosis have been extensively studied and details of new thrombophilic conditions are continually being discovered. Although there has been extensive research detailing various predispositions to thrombosis, uncertainties regarding their appropriate management continue. This review aims to highlight the various challenges involved in identifying those at risk; provide appropriate management options; and lastly present the current views on the development of new anticoagulants that are competing to replace the traditional agents.
PrandoniP, LensingAW, CogoA.The longterm clinical course of acute deep venous thrombosis.Ann Intern Med1996; 125: 1–7.
2.
AndersonFA, WheelerHB, GoldbergRJ.A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study.Arch Intern Med1991; 151: 933–8.
3.
ReesDS, CoxM, CleggJB.World distribution of factor V Leiden.Lancet1995; 346: 1133
4.
OlsonST, BjörkI, ShefferR, CraigPA, ShoreJD, ChoayJ.Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement.J Biol Chem1992; 267: 12528–38.
5.
TaitRC, WalkerID, PerryDJ.Prevalence of antithrombin deficiency in the healthy population.Br J Haematol1994; 87: 106–12.
6.
TaitRC, WalkerID, ReitsmaPH.Prevalence of protein C deficiency in the healthy population.Thromb Haemost1995; 73: 87–93.
7.
DykesAC, WalkerID, McMahonAD.A study of Protein S antigen levels in 3788 healthy volunteers: influence of age.Br J Haematol2001; 113: 636–41.
8.
SoutoJC, CollI, LlobeD.The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population.Thrombosis and Haemostasis1998; 80: 306–9.
9.
DayalS, WilsonKM, LeoL, ArningE, BottiglieriT, LentzSR.Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia.Blood2006; 108: 2237–43.
10.
HajjarKA.Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor.J Clin Invest1993; 91: 2873
11.
LeeR, FrenkelUP.Hyperhomocystinemia and thrombosis.Hematol Oncol Clin North Am2003; 17: 85
12.
BickRL.Antiphospholipid thrombosis syndromes.Hematol Oncol Clin North Am2003; 17: 115
13.
AmbrusJL, AmbrusCM, MinkIB, PickrenJW.Causes of death in cancer patients.J Med1975; 6: 61–4.
14.
BuraA, CailleuxN, BienvenuB.Incidence and prognosis of cancer associated with bilateral venous thrombosis: a prospective study of 103 patients.J Thromb Haemost2004; 2: 441–4.
15.
BeltingM, AhamedJ, RufW.Signalling of the tissue factor coagulation pathway in angiogenesis and cancer.Arterioscler Thromb Vasc Biol2005; 25: 1545–50.
16.
KhoranaAA, AhrendtSA, RyanCK.Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer.Clin Cancer Res2007; 13: 2870–5.
17.
LeeAY, LevineMN.Venous thromboembolism and cancer: risks and outcomes.Circulation2003; 107 (23 Suppl 1): 117–21.
18.
DonatiMB.Cancer and thrombosis.Haemostasis1994; 24: 128–31.
19.
KhoranaAA, FrancisCW, CulakovaE, LymanGH.Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study.Cancer2005; 104: 2822–9.
20.
KhoranaAA, KudererNM, CulakovaE, LymanGH, FrancisCW.Development and validation of a predictive model for chemotherapy-associated thrombosis.Blood2008; 111: 4902–7.
21.
BaglinT, GrayE, GreavesM.British Committee for Standards in Haematology Clinical guidelines for testing for heritable thrombophilia.Br J Haematol2010; 149: 209–20.
22.
GouldMK, DembitzerAD, DoyleRL, HastieTJ, GarberAM.Low-molecular-weight heparins compared with unfractionated heparin for treatment of deep venous thrombosis. A meta-analysis of randomized controlled trials.Ann Intern Med1999; 130: 800–9.
23.
QuinlanDJ, McQuillanA, EikelboomJW.Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials.Ann Intern Med2004; 140: 175–83.
24.
CohenM, DemersC, GurfinkelEP.A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.N Engl J Med1997; 337: 447–52.
DasSK, CohenAT, EdmondsonRA, MelissariE, KakkarVV.Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial.World J Surg1996; 20: 521–6.
27.
StangierJ.Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.Clin Pharmacokinet2008; 47: 285–95.
28.
ErikssonBI, DahlOE, RosencherN.Oral dabigatran etexilate versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.J Thromb Haemost2007; 5: 2178–85.
29.
ErikssonBI, DahlOE, RosencherN.Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial.Lancet2007; 370: 949–56.
30.
SchulmanS, KearonC, KakkarAK.Dabigatran versus warfarin in the treatment of acute venous thromboembolism.N Engl J Med2009; 361: 2342–52.
31.
ConnollySJ, EzekowitzMD, YusufS.RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med2009; 361: 1139–51.
32.
WeinzC, SchwarzT, KubitzaD, MueckW, LangD.Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.Drug Metab Dispos2009; 37: 1056–64.
33.
LassenMR, AgenoW, BorrisLC.Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.N Engl J Med2008; 358: 2776–86.
34.
TurpieAG, LassenMR, DavidsonBL.Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.Lancet2009; 373: 1673–80.
PatelMR, MahaffeyKW, GargJ.ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.N Engl J Med2011; 365: 883–91.
37.
RaghavanN, FrostCE, YuZ.Apixaban metabolism and pharmacokinetics after oral administration to humans.Drug Metab Dispos2009; 37: 74–81.
38.
LassenMR, GallusA, RaskobGE, PineoG, ChenD, RamirezLM.ADVANCE-3 Investigators Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement.N Engl J Med2010; 363: 2487–98.
39.
BullerH, DeitchmanD, PrinsM, SegersA.Botticelli Investigators Writing Committee Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.J Thromb Haemost2008; 6: 1313–8.
40.
SaviP, HeraultJP, DuchaussoyP.Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy.J Thromb Haemost2008; 6: 1697–706.
41.
BullerHR, CohenAT, DavidsonB.Idraparinux versus standard therapy for venous thromboembolic disease.N Engl J Med2007; 357: 1094–104.
42.
Equinox Investigators.Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.J Thromb Haemost2011; 9: 92–9.
43.
BijsterveldNR, MoonsAH, BoekholdtSM.Ability of recombinant factor Vila to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.Circulation2002; 106: 2550–4.
44.
EerenbergES, KamphuisenPW, SijpkensMK, MeijersJC, BullerHR, LeviM.Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.Circulation2011; 124: 1573–9.
45.
MannKG, BrummelK, ButenasS.What is all that thrombin for?J Thromb Haemost2003; 1: 1504–14.
46.
YinET, WesslerS.Heparin-accelerated inhibition of activated factor X by its natural plasma inhibitor.Biochim Biophys Acta1970; 201: 387–90.
47.
WesslerS, YinET.Theory and practice of minidose heparin in surgical patients. A status report.Circulation1973; 47: 671–6.
